Este sitio requiere JavaScript habilitado para funcionar correctamente. Modifique su configuración o utilice otro navegador para continuar.

      

Esta usted abandonando la página de GSK.

El enlace le llevará a una página mantenida por un tercero, que es el único responsable de su contenido. GSK no controla, no influencia ni aprueba el sitio. Opiniones, quejas o comentarios expresados en este sitio no deben atribuirse a GSK.

Aceptar

Cancelar

PATIENT IDENTIFICATION

How Can Patients Most Likely to Benefit From BENLYSTA Once-weekly Subcutaneous Injection Be Identified in Your Clinic?

  • Positive antinuclear antibody (ANA) test results (titre ≥ 1:80) 125
    AND one or both of the following:
    • Positive anti-dsDNA autoantibody (≥ 30 IU/mL) 125
    • Low complement (C3 and/or C4) (C3 < 90 mg/dL and/or C4 < 16 mg/dL) 125

AND/OR

  • SELENA-SLEDAI ≥ 10 1


In addition to high disease activity, patients likely to benefit from BENLYSTA subcutaneous injection are characterised by:

  • Wide range of organ domain involvement including: 125
  • History of recurrent flares 125
  • Fatigue 125

Patients on a treatment regimen consisting of any of the following (alone or in combination) 12:

  • Long-term corticosteroids or recent corticosteroids ≥ 7.5 mg/day
  • Immunosuppressants
  • Antimalarials
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Further reduction of SLE disease activity beyond standard therapy 1-5
  • Reduction of future severe flares and fatigue 1-5

Learn More About SLE Patients

What Next?

Click here to learn more about efficacy of BENLYSTA once-weekly subcutaneous injection

Additional Resources

How do I identify eligible patients in my practice?

*Based on the clinical trial data.

References:

  1. GlaxoSmithKline. Data on file.
  2. Doria A, Stohl W, Schwarting A, et al. Efficacy and safety of subcutaneous belimumab plus standard care in patients with SLE with low complement and positive anti-dsDNA. Ann Rheum Dis. 2016;75(Supp.2):70.
  3. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-731.
  4. Furie R, Petri M, Zamani O, et al. A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-3930.
  5. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343-1349.